serum-neurofilament

Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.

1. 52/100

   Serum neurofilament light chain and inflammatory cytokines as biomarkers for early detection of mild cognitive impairment

   ✓ Peer-reviewed alzhub usefulness score 52 out of 100. Scientific reports · 2024-04-20 · Biomarkers

   To investigate the association between serum neurofilament light chain (NfL) levels, inflammatory cytokines, and cognitive function to assess their utility in the early detection of mild cognitive impairment (MCI).

   • Biomarkers
   • Diagnosis
   • Early Stage
2. 59/100

   Serum neurofilament indicates accelerated neurodegeneration and predicts mortality in late-stage Parkinson's disease

   ✓ Peer-reviewed alzhub usefulness score 59 out of 100. NPJ Parkinson's disease · 2024-01-09 · Biomarkers

   Different stages of Parkinson's disease (PD) are defined by clinical criteria, while late-stage PD is marked by the onset of morbidity milestones and rapid clinical deterioration.

   • Biomarkers
   • Other Dementias
3. 43/100

   Serum neurofilament light chain as a surrogate of cognitive decline in sporadic and familial frontotemporal dementia

   ✓ Peer-reviewed alzhub usefulness score 43 out of 100. European journal of neurology · 2021-09-03 · Biomarkers

   Our findings highlight the potential of serum NfL as a useful surrogate end point of disease severity in upcoming targeted treatments.

   • Biomarkers
   • Genetics
   • Other Dementias
4. 55/100

   Comparison of CSF and serum neurofilament light and heavy chain as differential diagnostic biomarkers for ALS

   ✓ Peer-reviewed alzhub usefulness score 55 out of 100. Journal of neurology, neurosurgery, and psychiatry · 2021-08-20 · Biomarkers

   Our results demonstrate that CSF NfL and NfH as well as serum NfL are equally suited for the differential diagnosis of ALS, whereas serum NfH appears to be slightly less potent.

   • Biomarkers
   • Diagnosis
   • Other Dementias
5. 41/100

   CSF or serum neurofilament light added to α-Synuclein panel discriminates Parkinson's from controls

   ✓ Peer-reviewed alzhub usefulness score 41 out of 100. Movement disorders : official journal of the Movement Disorder Society · 2019-11-18 · Biomarkers

   CSF neurofilament contributes to a panel of CSF α-synuclein species in differentiating PD patients from healthy controls.

   • Biomarkers
   • Other Dementias
6. 53/100

   Serum neurofilament light chain is a discriminative biomarker between frontotemporal lobar degeneration and primary psychiatric disorders

   ✓ Peer-reviewed alzhub usefulness score 53 out of 100. Journal of neurology · 2019-10-08 · Biomarkers

   Due to the significant clinical overlap between frontotemporal lobar degeneration (FTLD) spectrum disorders and late-onset primary psychiatric disorders (PPD), diagnostic biomarkers reflecting the different underlying pathophysiologies are urgently needed.

   • Biomarkers
   • Other Dementias
7. 64/100

   Longitudinal measurement of serum neurofilament light in presymptomatic familial Alzheimer's disease

   ✓ Peer-reviewed alzhub usefulness score 64 out of 100. Alzheimer's research & therapy · 2019-02-20 · Biomarkers

   There is evidence that serum NfL is increased more than a decade before the onset of clinical symptoms in FAD and rises thereafter.

   • Biomarkers
   • Genetics

All topic tags with their study counts